OVERVIEW

• Review of Basics
• Definition
• Goals of NIV
• Types
• Advantages and Disadvantages
• Indications and Contraindications
• Interface
• Modes of NIV
• Guidelines for Initiation and Termination
• Complications
• Evidence for use
• Conclusion
Respiratory failure is a syndrome where the respiratory system fails in one or both of its gas exchange functions:
- Oxygen uptake
- Carbon dioxide elimination

Respiratory failure may be acute, chronic, or acute on chronic

Derangements in ABG and acid-base status
- Acute – life threatening
- Chronic – less dramatic

Hypoxemia and/or hypercapnea
- Type 1 – Hypoxemia, PaO2 <60 mmHg, normal or low PaCO2
- Type 2 – Hypoxemia and hypercapnea
CAUSES OF RESPIRATORY FAILURE

• Alveolar filling processes
• Pulmonary vascular disease
• Diseases causing airways obstruction (central or distal)
• Hypoventilation: decreased central drive
• Hypoventilation: peripheral nervous system/respiratory muscle dysfunction
• Hypoventilation: chest wall and pleural disease
• Increased ventilatory demand
HYPOXEMIC RESPIRATORY FAILURE

• Most common form of respiratory failure
• Associated with virtually all acute diseases of the lung involving fluid filling or collapse of alveolar units
  • Pulmonary edema, pneumonia, ARDS, pulmonary embolism
• Caused by one of the four mechanisms
  • V/Q mismatch
  • Shunt
  • Diffusion Impairment
  • Hypoventilation
• V/Q mismatch is the most common and most important
  • Areas of low ventilation relative to perfusion
• Shunts – intracardiac or intrapulmonary
HYPERCAPNIC RESPIRATORY FAILURE

- Characterized by PaCO2 >50 mmHg
- Hypoxemia is common
- pH depends on HCO3 level, dependent on duration of hypercapnia
- Seen with opiate overdose, neuromuscular disease, chest wall abnormalities, and severe airway disorders (status asthmaticus, severe COPD)
- Acute failure can develop over minutes to hours, pH <7.3
- Chronic failure develops over days or longer, renal compensation, pH only slightly decreased
<table>
<thead>
<tr>
<th>Hypoxemic Respiratory Failure</th>
<th>Hypercapnic Respiratory Failure</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Known as:</strong></td>
<td><strong>Known as:</strong></td>
</tr>
<tr>
<td>Type I ARF, Lung Failure,</td>
<td>Type II ARF, Pump Failure,</td>
</tr>
<tr>
<td>Oxygenation Failure,</td>
<td>Ventilatory Failure</td>
</tr>
<tr>
<td>Respiratory Insufficiency</td>
<td></td>
</tr>
<tr>
<td><strong>Definition:</strong></td>
<td><strong>Definition:</strong></td>
</tr>
<tr>
<td>The failure of lungs and</td>
<td>The failure of the lungs to</td>
</tr>
<tr>
<td>heart to provide adequate</td>
<td>eliminate adequate CO₂</td>
</tr>
<tr>
<td>O₂ to meet metabolic needs</td>
<td></td>
</tr>
<tr>
<td><strong>Criteria:</strong></td>
<td><strong>Criteria:</strong></td>
</tr>
<tr>
<td>PaₐO₂ &lt; 60 mmHg on FiO₂ ≥.50</td>
<td>Acute ↑ in PaCO₂ &gt; 50 mmHg</td>
</tr>
<tr>
<td>or</td>
<td>or</td>
</tr>
<tr>
<td>PaₐO₂ &lt; 40 mmHg on any FiO₂</td>
<td>Acutely above normal baseline</td>
</tr>
<tr>
<td>SaO₂ &lt; 90</td>
<td>in COPD with concurrent ↓ in pH</td>
</tr>
<tr>
<td></td>
<td>&lt; 7.30</td>
</tr>
<tr>
<td><strong>Basic Causes:</strong></td>
<td><strong>Basic Causes:</strong></td>
</tr>
<tr>
<td>R-L shunt</td>
<td>Pump failure (drive, muscles,</td>
</tr>
<tr>
<td>V/Q mismatch</td>
<td>WOB)</td>
</tr>
<tr>
<td>Alveolar hypoventilation</td>
<td>↑ CO₂ production</td>
</tr>
<tr>
<td>Diffusion defect</td>
<td>R-L shunt</td>
</tr>
<tr>
<td>Inadequate FiO₂</td>
<td>↑ Deadspace</td>
</tr>
</tbody>
</table>
CAUSES OF HYPOXEMIC RESPIRATORY FAILURE

- Pneumonia
- Cardiogenic pulmonary edema
- Noncardiogenic pulmonary edema
- Pulmonary fibrosis
- COPD
- Asthma
- Pulmonary embolism
- Pulmonary arterial hypertension
- Hypersensitivity pneumonitis
- Pneumoconiosis
- Bronchiectasis
- Congenital heart disease
- Shunts
- Massive pleural effusion
- Pneumothorax
- Pulmonary hemorrhage
CAUSES OF HYPERCAPNIC RESPIRATORY FAILURE

- COPD
- Status Asthmaticus
- Drug overdose
- Poisonings
- Myasthenia gravis
- Poliomyelitis
- Guillan-Barre
- Polyneuropathy
- Spinal injury/Head injury

- Primary alveolar hypoventilation
- Obesity hypoventilation syndrome
- Severe pulmonary edema
- Severe ARDS
- Myxedema
- Tetanus
CASE PRESENTATION

- **HPI:** 75 yo WM with a hx of severe COPD and OSA, noncompliant with PAP therapy but wears oxygen 2 lpm hs, presents to the hospital with AECOPD. After several bronchodilator treatments he remains dyspneic, wheezing, and using accessory muscles to breathe.

- **VS:** T 37.2C, BP 160/95 mmHg, HR 100 bpm, RR 32 bpm, 98kg, 65 in height

- Exam AAOx3, mild respiratory distress, RRR no m/r/g, Decreased BS with expiratory wheeze bilaterally, Abdomen benign, Extremities without c/c/e

- **Labs:** ABG 7.25/60/65/ on 3 lpm oxygen

- **CXR:** hyperinflation, no infiltrates, effusion, edema
DEFINITION

• Noninvasive ventilation (NIV) refers to the delivery of mechanical ventilation to the lungs using techniques that do not require an invasive artificial airway (endotracheal tube, tracheostomy)

• Goals:
  • Provide time for the cause of respiratory failure to resolve and improve gas exchange
  • Overcome auto-PEEP
  • Unload the respiratory muscle
  • Decrease dyspnea
  • Avoid Endotracheal Intubation
  • Avoid complications
TYPES OF NIV

- **Negative Pressure NIV**
  - Main means of NIV during the early 1900’s
  - Extensively used during the polio epidemics
  - Tank ventilator “iron lung”
  - Cuirass, Jacket ventilator, Hayek oscillator

- **Positive Pressure NIV**
  - Positive pressure delivered through mask
  - CPAP
  - BIPAP
  - AVAPS
  - ASV
NEGATIVE PRESSURE VENTILATION

• Applies negative pressure intermittently around the patient’s body or chest wall resulting in a pressure drop around the thorax
• Negative pressure is transmitted to the pleural space and alveoli creating a pressure gradient between the lungs and mouth
• As a result gas flows into the lungs
• Patient’s head (upper airway) is exposed to the room
• New York Times May 2009
• “Martha Mason, who wrote a book about her decades in an iron lung, dies at age 71.”
HOW DOES NIV WORK?

- Reduction in inspiratory muscle work and avoidance of respiratory muscle fatigue
- Augments tidal volume
- Improves compliance by reversing microatelectasis
- Overcome intrinsic PEEP
- Enhanced cardiovascular function (afterload reduction)
- Stent the airway
- Reduce CO2 production
NIV FOR HYPOXEMIC RESPIRATORY FAILURE

- Increased FIO2
- PEEP
  - Alveolar recruitment
  - Increased V/Q
  - Decreased Shunt
  - Increased FRC
  - Decreased RR and WOB
NIV FOR HYPERCAPNIC RESPIRATORY FAILURE

- Offsets auto-PEEP
- Reduce airway resistance
- Improve VT, VE, PaCO2
ADVANTAGES

- Noninvasive
- Correction of gas exchange
- Improve lung mechanics
- Reduce resistive work imposed by invasive ventilation
- Ventilates effectively with lower pressures
- Flexibility in initiation/termination
- Intermittent application
- Patient comfort
- Correct mental status
- Preserves speech/swallowing/expectoration

- Reduces need for nasogastric tubes
- Reduce need for sedation
- Avoids complications of ETT
  - Trauma/injury, aspiration
- Avoids complications of invasive ventilation
  - Infection-pneumonia, sepsis, sinusitis
  - GI bleed
  - DVT
- Less cost
- Decrease mortality associated with respiratory failure
- Assist in end of life care
DISADVANTAGES

• System
  • Slower correction of gas exchange abnormalities
  • Time commitment/attention
  • Gastric distention

• Interface
  • Leaks
  • Skin necrosis/rash
  • Eye/ear irritation
  • Sinus pressure

• Airway
  • Aspiration
  • Limited secretion clearance
CONTRAINDICATIONS

- Cardiopulmonary arrest
- Hemodynamic instability
- Nonrespiratory multiorgan failure
- Mental status change
  - Uncooperative
  - Encephalopathy (GCS <10)
  - Seizure
- Inability to protect airway
  - Secretions
- Recent Trauma
  - Facial/angioedema
  - Upper airway surgery

- Facial deformities
- +/- edentulous
- GI Bleed/surgery
- Intractable emesis
- Tumors:
  - Head/neck
  - Extrinsic compression of airway
- Airway obstruction
- Recent neurosurgery
- Burns
- Untreated pneumothorax
INTUBATE EARLY!

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical assessment</strong></td>
<td></td>
</tr>
<tr>
<td>Apnea</td>
<td></td>
</tr>
<tr>
<td>Stridor</td>
<td></td>
</tr>
<tr>
<td>Severely depressed mental status</td>
<td></td>
</tr>
<tr>
<td>Flail chest</td>
<td></td>
</tr>
<tr>
<td>Inability to clear respiratory secretions (eg, excessive secretions, loss of protective reflexes, neurovascular failure)</td>
<td></td>
</tr>
<tr>
<td>Trauma to mandible, larynx, trachea</td>
<td></td>
</tr>
<tr>
<td><strong>Loss of ventilatory reserve</strong></td>
<td></td>
</tr>
<tr>
<td>Respiratory rate</td>
<td>&gt;35 breaths/min</td>
</tr>
<tr>
<td>Tidal volume</td>
<td>&lt;5 mL/kg</td>
</tr>
<tr>
<td>Vital capacity</td>
<td>&lt;10 mL/kg</td>
</tr>
<tr>
<td>Negative inspiratory force</td>
<td>Weaker than −25 cm H₂O (2.44 kPa)</td>
</tr>
<tr>
<td>Minute ventilation</td>
<td>&lt;10 L/min</td>
</tr>
<tr>
<td>Rise in $\text{PaCO}_2$</td>
<td>&gt;10 mmHg (1.33 kPa)</td>
</tr>
<tr>
<td><strong>Refractory hypoxemia</strong></td>
<td></td>
</tr>
<tr>
<td>Alveolar-arterial gradient ($\text{FiO}_2 = 1$)</td>
<td>&gt;450</td>
</tr>
<tr>
<td>$\text{PaO}_2$/$\text{PAO}_2$</td>
<td>&lt;0.15</td>
</tr>
<tr>
<td>$\text{PaO}_2$ with supplemental O₂</td>
<td>&lt;55 mmHg (7.32 kPa)</td>
</tr>
</tbody>
</table>

$\text{PaCO}_2$: arterial tension of carbon dioxide; $\text{FiO}_2$: fraction of inspired oxygen; $\text{PaO}_2$: arterial tension of oxygen; $\text{PAO}_2$: alveolar tension of oxygen.
CANDIDATES FOR NIV

• Clinical judgement supersedes
• Cooperative patient
• Dyspnea/increased WOB
• Hypoxemia and/or hypercapnia
• Respiratory acidosis

• Clinical Conditions
  • COPD
    • stable
    • acute exacerbation
  • Cardiogenic Pulmonary edema
  • Immunosuppressed
  • DNR/DNI

• Selected patients:
  • COPD + Pneumonia
  • Facilitate weaning
  • Asthma
  • OSA/OHS
  • Cor pulmonale
  • ARDS
  • Neuromuscular disease
  • Restrictive thoracic disorders
  • Cystic Fibrosis
  • Post extubation
  • Post op respiratory failure
  • Bronchoscopy
Evidence-based Utilization of Noninvasive Ventilation and Patient Outcomes

Anuj B. Mehta\textsuperscript{1,2,3}, Ivor S. Douglas\textsuperscript{2,3}, and Allan J. Walkey\textsuperscript{4,5}

Abstract

Rationale: Strong evidence supports use of noninvasive ventilation (NIV) for patients with respiratory distress from chronic obstructive pulmonary disease and heart failure (strong evidence conditions [SECs]). Despite unclear benefits of NIV for other causes of acute respiratory failure, utilization for conditions with weaker evidence is increasing, despite evidence demonstrating higher mortality for patients who suffer NIV failure (progression from NIV to invasive mechanical ventilation [IMV]) compared with being treated initially with IMV.

Results: Among 22,706 hospitalizations with NIV as the initial ventilatory strategy, 6,820 (30.0\%) had SECs. Patients with SECs had lower risk of NIV failure than patients with weak evidence conditions (8.1 vs. 18.2\%, $P < 0.0001$). Regardless of underlying diagnosis, patients admitted to hospitals with greater use of NIV for SECs had lower risk of NIV failure (Quartile 4 vs. Quartile 1 adjusted odds ratio = 0.62; 95\% CI = 0.49–0.80). Even patients without an SEC benefited from admission to hospitals that used NIV more often for patients with SECs (Quartile 4 vs. Quartile 1 adjusted odds ratio for NIV failure = 0.68; 95\% CI = 0.52–0.88).

Conclusions: Most patients who received NIV did not have conditions with strong supporting evidence for its use with wide institutional variation in patient selection for NIV. Surprisingly, we found that all patients, even those without an SEC, benefited from admission to hospitals with greater evidence-based utilization of NIV, suggesting a “hospital effect” that is synergistic with patient selection.
OUTCOMES OF NONINVASIVE VENTILATION FOR ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN THE UNITED STATES 1998-2008

An estimated 7,511,267 admissions for acute exacerbations occurred from 1998 to 2008.

We used data from the Nationwide Inpatient Sample of the Healthcare Cost and Utilization Project (HCUP-NIS) from 1998 to 2008.

Since 1988, HCUP-NIS has collected patient-level clinical and resource use data included in the discharge abstract on about 5 to 8 million inpatient hospital stays from close to a 1,000 hospitals. This represents an approximately 20% stratified probability sample of all United States acute-care, nongovernmental hospitals each year.
Temporal trends in the use of noninvasive positive pressure ventilation (NIPPV) and invasive mechanical ventilation (IMV) as the initial form of respiratory support in patients hospitalized with acute exacerbations of chronic obstructive pulmonary disease (COPD) in the United States, 1998–2008.

OUTCOMES OF NONINVASIVE VENTILATION FOR ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN THE UNITED STATES 1998-2008

Length-of-stay in days for patients admitted with acute exacerbations of chronic obstructive pulmonary disease grouped by type or respiratory support used during the hospitalization, 1998–2008.

IMV = invasive mechanical ventilation; NIPPV = noninvasive positive pressure ventilation.

NONINVASIVE POSITIVE PRESSURE VENTILATION FOR TREATMENT OF RESPIRATORY DUE TO EXACERBATIONS OF COPD (REVIEW)

• Data from quality RCTs show benefit of NIV as FIRST line intervention in addition to usual medical care to ARF secondary to acute exacerbation of COPD in all suitable patients

• Use EARLY in the course of respiratory failure as a means of reducing the likelihood of endotracheal intubation, treatment failure, and mortality

NIV IN COPD EXACERBATION

- Multiple RCTs support a success rate of 80-85%
- Shown to improve respiratory acidosis
- Decrease work of breathing, dyspnea, and complications including VAP, LOS hospital
- Reduce mortality and intubation rates
• Large observational study 25,628 patients admitted with AECOPD
• Early NIV use confirmed significant reduction in:
  • Hospital mortality
  • Hospital acquired pneumonia
  • Duration of mechanical ventilation

NIV AND STABLE COPD

• NIV is increasingly used in stable very severe COPD
• NIV and oxygen therapy in selected patients with pronounced daytime hypercapnia
• COPD/OSA overlap
• Clear benefits in both survival and risk of hospital admission
NONINVASIVE POSITIVE PRESSURE VENTILATION AS A WEANING STRATEGY FOR INTUBATED ADULTS WITH RESPIRATORY FAILURE (REVIEW)

- 12 trials of moderate to good quality
- Compared to IPPV strategy, NPPV significantly reduced:
  - Mortality (RR 0.55)
  - VAP (RR 0.29)
  - ICU LOS (WMD -6.27 days) and hospital LOS (WMD -7.19 days)
  - Total duration of ventilation (WMD -5.64 days)
  - Duration of endotracheal mechanical ventilation (WMD -7.81 days)
    - WMD = weighted mean difference
- Compared to IPPV, noninvasive weaning had no effect on weaning failures or the duration of ventilation related to weaning
- Concluded: consistent, positive effect on mortality and VAP

The Role of Noninvasive Ventilation in the Ventilator Discontinuation Process

Dean R Hess PhD RRT FAARC

Introduction
NIV to Shorten the Length of Invasive Ventilation
NIV to Prevent Extubation Failure
NIV to Rescue Failed Extubation
When to Stop
Equipment and Resources
Summary and Recommendations

In recent years, there has been increasing interest in the use of noninvasive ventilation (NIV) in the post-extubation period to shorten the length of invasive ventilation, to prevent extubation failure, and to rescue a failed extubation. The purpose of this review is to summarize the evidence related to the use of NIV in these settings. NIV can be used to **allow earlier extubation** in selected patients who do not successfully complete a spontaneous breathing trial (SBT). Its use in this setting should be restricted to patients who are intubated during an exacerbation of COPD or patients with **neuromuscular disease**. This category of patients should be good candidates for NIV and should be extubated directly to NIV. In patients who successfully complete an SBT, but are at risk for extubation failure, NIV can be used to **prevent extubation failure**. These patients should also be good candidates for NIV and should be extubated directly to NIV. NIV should be used cautiously in patients who successfully complete an SBT, but develop respiratory failure within 48 hours post-extubation. In this setting, NIV is **indicated only in patients with hypercapnic respiratory failure**. Reintubation should not be delayed if NIV is not immediately successful in reversing the post-extubation respiratory failure. Evidence does not support routine use of NIV post-extubation.
NONINVASIVE POSITIVE PRESSURE VENTILATION (CPAP OR BILEVEL NIPPV) FOR CARDIOGENIC PULMONARY EDEMA (REVIEW)

- Included 32 studies
- NIV is a safe and effective intervention for the treatment of adult patients with acute cardiogenic pulmonary edema
- Evidence to date on the potential benefit of NIV in reducing mortality is entirely derived from small trials and further large scale trials are needed

NIV FOR THE IMMUNOCOMPROMISED PATIENT

- Immunocompromised patients are particularly exposed to increased infectious risk related to invasive mechanical ventilation.
- Multiple RCTs support, whenever possible, NIV should be tried first.
- Antonelli et al. JAMA 2000
  - 40 subjects with solid organ transplantation who developed hypoxemic respiratory failure
  - NIV v oxygen support
  - NIV had lower rates of intubation and mortality
- Hilbert et al. NEJM 2001
  - 52 patients with hypoxemia
  - NIV v oxygen support
  - NIV had lower rates of intubation and mortality
NIV FOR THE IMMUNOCOMPROMISED PATIENT

- Trends toward better survival
- Trends towards decreased need for intubation and invasive ventilation
- No significant clinical advantage
  - Mortality, infection, intubation, LOS
- 374 patients (50/50 split)

Lemiale V et al. JAMA 2015
Noninvasive Ventilation for Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome

Stefano Nava MD, Ania Schreiber MD, and Guido Domenighetti MD

Introduction
Physiological Rationale
Meta-analyses and Systematic Reviews
NIV to Prevent Endotracheal Intubation in ALI/ARDS Patients
NIV as an Alternative to Endotracheal Intubation in ALI/ARDS Patients
Summary

Few studies have been performed on noninvasive ventilation (NIV) to treat hypoxic acute respiratory failure in patients with acute lung injury (ALI) or acute respiratory distress syndrome (ARDS). The outcomes of these patients, for whom endotracheal intubation is not mandatory, depend on the degree of hypoxia, the presence of comorbidities and complications, and their illness severity. The use of NIV as an alternative to invasive ventilation in severely hypoxemic patients with ARDS (ie, $P_{aO_2}/F_{IO_2} < 200$) is not generally advisable and should be limited to hemodynamically stable patients who can be closely monitored in an intensive care unit by highly skilled staff. Early NIV application may be extremely helpful in immunocompromised patients with pulmonary infiltrates, in whom intubation dramatically increases the risk of infection, pneumonia, and death. The use of NIV in patients with severe acute respiratory syndrome and other airborne diseases has generated debate, despite encouraging clinical results, mainly because of safety issues. Overall, the high rate of NIV failure suggests a cautious approach to NIV use in patients with ALI/ARDS, including early initiation, intensive monitoring, and prompt intubation if signs of NIV failure emerge. Key words:
Extubation of Patients With Neuromuscular Weakness

A New Management Paradigm

John Robert Bach, MD; Miguel R. Gonçalves, PT; Irram Hamdani, MD; and Joao Carlos Winck, MD, PhD

Background: Successful extubation conventionally necessitates the passing of spontaneous breathing trials (SBTs) and ventilator weaning parameters. We report successful extubation of patients with neuromuscular disease (NMD) and weakness who could not pass them.

Methods: NMD-specific extubation criteria and a new extubation protocol were developed. Data were collected on 157 consecutive “unweanable” patients, including 83 transferred from other hospitals who refused tracheostomies. They could not pass the SBTs before or after extubation. Once the pulse oxyhemoglobin saturation (SpO₂) was maintained at ≥ 95% in ambient air, patients were extubated to full noninvasive mechanical ventilation (NIV) support and aggressive mechanically assisted coughing (MAC). Rather than oxygen, NIV and MAC were used to maintain or return the SpO₂ to ≥ 95%. Extubation success was defined as not requiring reintubation during the hospitalization and was considered as a function of diagnosis, preintubation NIV experience, and vital capacity and assisted cough peak flows (CPF) at extubation.

Results: Before hospitalization 96 (61%) patients had no experience with NIV, 41 (26%) used it < 24 h per day, and 20 (13%) were continuously NIV dependent. The first-attempt protocol extubation success rate was 95% (149 patients). All 98 extubation attempts on patients with assisted CPF ≥ 160 L/min were successful. The dependence on continuous NIV and the duration of dependence prior to intubation correlated with extubation success (P < .005). Six of eight patients who initially failed extubation succeeded on subsequent attempts, so only two with no measurable assisted CPF underwent tracheotomy.

Conclusions: Continuous volume-cycled NIV via oral interfaces and masks and MAC with oximetry feedback in ambient air can permit safe extubation of unweanable patients with NMD.
Noninvasive Ventilation Reduces Intubation in Chest Trauma-Related Hypoxemia

A Randomized Clinical Trial

Gonzalo Hernandez, MD, PhD; Rafael Fernandez, MD, PhD; Pilar Lopez-Reina, MD; Rafael Cuena, MD; Ana Pedrosa, MD; Ramon Ortiz, MD; and Paloma Hiradier, MD

Background: Guidelines for noninvasive mechanical ventilation (NIMV) recommend continuous positive airway pressure in patients with thoracic trauma who remain hypoxic despite regional anesthesia. This recommendation is rated only by level C evidence because randomized controlled trials in this specific population are lacking. Our aim was to determine whether NIMV reduces intubation in severe trauma-related hypoxemia.

Methods: This was a single-center randomized clinical trial in a nine-bed ICU of a level I trauma hospital. Inclusion criteria were patients with \( P_{aO_2}/FIO_2 < 200 \) for > 8 h while receiving oxygen by high-flow mask within the first 48 h after thoracic trauma. Patients were randomized to remain on high-flow oxygen mask or to receive NIMV. The interface was selected based on the associated injuries. Thoracic anesthesia was universally supplied unless contraindicated. The primary end point was intubation; secondary end points included length of hospital stay and survival. Statistical analysis was based on multivariate analysis.

Results: After 25 patients were enrolled in each group, the trial was prematurely stopped for efficacy because the intubation rate was much higher in controls than in NIMV patients (10 [40%] vs 3 [12%], \( P = .02 \)). Multivariate analysis adjusted for age, gender, chronic heart failure, and other variables independently related to intubation (odds ratio, 0.12; 95% CI, 0.02-0.61; \( P = .01 \)). Length of hospital stay was shorter in NIMV patients (14 vs 21 days \( P = .001 \)), but no differences were observed in survival or other secondary end points.

Conclusion: NIMV reduced intubation compared with oxygen therapy in severe thoracic trauma-related hypoxemia.

Trial registration: clinicaltrials.gov; identifier: NCT 00557752.

CHEST 2010; 137(1):74–80
Noninvasive Ventilation of Patients with Acute Respiratory Distress Syndrome
Insights from the LUNG SAFE Study

Abstract

**Rationale:** Noninvasive ventilation (NIV) is increasingly used in patients with acute respiratory distress syndrome (ARDS). The evidence supporting NIV use in patients with ARDS remains relatively sparse.

**Objectives:** To determine whether, during NIV, the categorization of ARDS severity based on the \( \text{Pa}_O_2/\text{Fi}_O_2 \) Berlin criteria is useful.

**Methods:** The LUNG SAFE (Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure) study described the management of patients with ARDS. This substudy examines the current practice of NIV use in ARDS, the utility of the \( \text{Pa}_O_2/\text{Fi}_O_2 \) ratio in classifying patients receiving NIV, and the impact of NIV on outcome.

**Measurements and Main Results:** Of 2,813 patients with ARDS, 436 (15.5%) were managed with NIV on Days 1 and 2 following fulfillment of diagnostic criteria. Classification of ARDS severity based on \( \text{Pa}_O_2/\text{Fi}_O_2 \) ratio was associated with an increase in intensity of ventilatory support, NIV failure, and intensive care unit (ICU) mortality. NIV failure occurred in 22.2% of mild, 42.3% of moderate, and 47.1% of patients with severe ARDS. Hospital mortality in patients with NIV success and failure was 16.1% and 45.4%, respectively. NIV use was independently associated with increased ICU (hazard ratio, 1.446 [95% confidence interval, 1.159–1.805]), but not hospital, mortality. In a propensity matched analysis, ICU mortality was higher in NIV than invasively ventilated patients with a \( \text{Pa}_O_2/\text{Fi}_O_2 \) lower than 150 mm Hg.

**Conclusions:** NIV was used in 15% of patients with ARDS, irrespective of severity category. NIV seems to be associated with higher ICU mortality in patients with a \( \text{Pa}_O_2/\text{Fi}_O_2 \) lower than 150 mm Hg.

Clinical trial registered with www.clinicaltrials.gov (NCT 02010073).

**Keywords:** noninvasive ventilation; acute respiratory distress syndrome
NIV IN ASTHMA

- Role for NIV in asthma not well defined
- Alternative to invasive mechanical ventilation in patients who have failed standard treatment
- Prevent need for invasive mechanical ventilation in patients who do not have substantial impairment in gas exchange

Noninvasive Ventilation in Severe Acute Asthma

Jhaymie L Cappiello MSc RRT-ACCS and Michael B Hocker MD MHS
NIV IN THE DNR/DNI PATIENT

• Controversy – ethical, cost
• Not yet known if palliative NIV increases duration of life/extends the dying process
• Benefits
  • Patient well being? Comfort?
  • Family satisfaction/experience
• Clinician perspective
• Clarify goals of care
  • Explicit parameters for success/failure be set
  • Provide experienced personnel
• Future studies needed

CASE PRESENTATION

• HPI: 75 yo WM with a hx of severe COPD and OSA, noncompliant with PAP therapy but wears oxygen 2 lpm hs, presents to the hospital with AECOPD. After several bronchodilator treatments he remains dyspneic, wheezing, and using accessory muscles to breathe.

• VS: T 37.2C, BP 160/95 mmHg, HR 100 bpm, RR 32 bpm, 98kg, 65 in height

• Exam AAOx3, mild respiratory distress, RRR no m/r/g, Decreased BS with expiratory wheeze bilaterally, Abdomen benign, Extremities without c/c/e

• Labs: ABG 7.25/60/65/ on 3 lpm oxygen

• CXR: hyperinflation, no infiltrates, effusion, edema
MULTIDISCIPLINARY APPROACH

- Physician
- Respiratory
- Nurse
- Others

- Patient
- Disease
- Goals

Skills
- Interprofessional Rounding
- Monitoring
- Protocols/Processes

Selection
- Ventilator
- Masks
- Adjuncts

Teamwork

Equipment
PATIENT SELECTION

• Step 1
  • Is the etiology of respiratory failure likely to respond favorably to NIV?

• Step 2
  • Clinical presentation
  • ABG analysis
  • Monitored location
    • Pre-hospital
    • ED/Floor/Stepdown Unit
    • ICU

• Step 3
  • Exclude situations where NIV would be unsafe
SUCCESSFUL APPLICATION OF NIV

1. Choose Ventilator
2. Choose Interface
3. Choose Settings
4. Work with Patient, Reassess and Adjust
5. Assess for Success/Failure/Weaning
MODES OF NIV

- CPAP
- NIV with PSV (BIPAP)
- Average Volume Assured Pressure Support (AVAPS)
- Adaptive Servo Ventilation (ASV) or AutoSV
- High Flow nasal cannula

- Deliver with oxygen to maintain adequate oxygen saturation
- Humidification
MODES OF NIV
MODES OF NIV

Pressure Modes
• Better tolerated than volume-cycled mode
• Constant positive airway pressure (CPAP)
• Bilevel or biphasic positive airway pressure (BiPAP)
• Pressure support ventilation (PSV)

Volume Modes
• Initial TV range 10-15 ml/kg
• Control
• Assist control
INTERFACE

- Nasal
- Full Face
- Nasal Pillows
- Hybrid
- Oral
- Total Face
ORONASAL MASK

- Faceplate does not obstruct users’ vision
- Entrainment Valve allows patient to breathe room air if pressure is discontinued as in the case of power failure
- Built-in Exhalation Ports provide continuous leak path in the circuit
- Headgear straps attach to Velcro hooks for secure placement
- URESF 1003052
- Quick Release Cord enables fast removal of the mask
- Pressure Pickoff allows connection of a proximal pressure line or monitoring device
HELMET INTERFACE

• Equally tolerated
•Effective in ameliorating gas exchange
•Decreased inspiratory effort but less efficient
•Limited patient-ventilator interaction
# NASAL VS ORONASAL MASK

<table>
<thead>
<tr>
<th>Variables</th>
<th>Nasal</th>
<th>Oronasal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comfort</td>
<td>+++</td>
<td>++</td>
</tr>
<tr>
<td>Claustrophobia</td>
<td>+</td>
<td>++</td>
</tr>
<tr>
<td>Rebreathing</td>
<td>+</td>
<td>++</td>
</tr>
<tr>
<td>Lowers CO2</td>
<td>+</td>
<td>++</td>
</tr>
<tr>
<td>Permits expectoration</td>
<td>++</td>
<td>+</td>
</tr>
<tr>
<td>Permits speech</td>
<td>++</td>
<td>+</td>
</tr>
<tr>
<td>Permits eating</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Function if nose obstructed</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Interface</td>
<td>Advantages</td>
<td>Disadvantages</td>
</tr>
<tr>
<td>-------------------</td>
<td>-------------------------------------------------</td>
<td>------------------------------------------------------------</td>
</tr>
<tr>
<td>Nasal Mask</td>
<td>Comfort, less dead space, less aspiration</td>
<td>Mouth leak, nasal resistance, irritation</td>
</tr>
<tr>
<td>Nasal Pillows</td>
<td>Comfort (e.g. glasses), fit, headgear</td>
<td>Mouth leak, nasal resistance, irritation</td>
</tr>
<tr>
<td>Oronasal Mask</td>
<td>Better leak control, Mouth breathers</td>
<td>Aspiration risk, dead space, speaking/eating</td>
</tr>
<tr>
<td>Mouthpiece</td>
<td>Little dead space, no headgear</td>
<td></td>
</tr>
<tr>
<td>Total Face mask</td>
<td>Easier to fit, maybe more comfortable for some</td>
<td>Greater dead space, dry eyes, aerosolized meds</td>
</tr>
<tr>
<td>Helmet</td>
<td>One size fits all, less skin breakdown, comfort?</td>
<td>Rebreathing, synchrony, meds, less respiratory unloading</td>
</tr>
</tbody>
</table>
• Full face (oronasal) is most commonly used in ARF
• Explain the modality and provide reassurance
• Hold the mask in place until patient is:
  • Comfortable
  • In synchrony with the ventilator
• Secure the mask avoiding a tight fit
• Passage of two fingers beneath head straps
• Allow small air leaks if exhaled VT is adequate
• Skin patch to minimize abrasion and necrosis nasal bridge and skin
• Head of bed elevated to avoid aerophagia
• Bronchodilator administration (preferably off NIV, or delivered through the circuit)
• Avoid nasogastric tubes
HOW DO WE SUPPLY NIPPV TO THE PATIENT? CPAP

• CPAP - applies a single pressure throughout the entire respiratory cycle
  • Creates “pneumatic splint” for upper airway
  • It does not augment TV but it does increase FRC
    • Improve lung compliance
    • Open collapsed alveoli
    • Improve oxygenation
    • Decrease work of breathing
  • Decrease LV transmural pressure, decrease afterload and increase CO
  • Start at 5 cmH2O
  • Use higher pressure with obese patients and/or OSA
HOW DO WE SUPPLY NIPPV TO THE PATIENT? BIPAP

• NIV with PSV (BiPAP)
  • A specific pressure is applied to the airway for the duration of inspiration (IPAP)
  • A second pressure applied during expiration (EPAP)
  • IPAP - ventilation
  • EPAP – oxygenation
  • IPAP – EPAP = PSV

• Minimum difference between I and E no less than 5 cm H2O
• S mode, S/T mode
• TV varies
  • Determined by degree of IPAP
  • Patient effort
  • Lung compliance
AVERAGE VOLUME ASSURED PRESSURE SUPPORT - AVAPS

- **Settings**
  - Target TV
  - IPAP range (PSV varies)
  - EPAP
  - S, S/T, PC, T, auto
- Pressure and Volume limited
- Sensation of breathlessness
  - Increase minimum IPAP
- Example
  - Set TV
  - IPAP varies with effort
    - Wake v Sleep

**AVAPS Settings**

1. Set the Target Tidal Volume
   - To 8ml/kg of the ideal weight and adjust depending on patient pathology

2. Set IPAP Limits
   - IPAP max = 25 to 50 cmH₂O depending on patient condition and maximum pressure available on the machine
   - IPAP min = EPAP + 4 cmH₂O depending on patient condition
AVAPS
AVAPS

- COPD
- Obesity Hypoventilation
- Restrictive disease
- Neuromuscular disorders
AVAPS

- Should not be used in the acute setting where rapid IPAP changes are needed to achieve desired TV
- IPAP does not change more than 2.5 cmH2O within one minute
- Used in patients with chronic respiratory failure in need of ventilatory support
HIGH FLOW NASAL CANNULA
OXYGEN THERAPY
HIGH FLOW NASAL CANNULA

- Maintains constant FiO2
- Increased CO2 clearance via nasopharyngeal dead space washout
- Inspiratory flow varies, TV varies
- PEEP affect, resistance against expiratory flow and increases airway pressure
HIGH FLOW NASAL CANNULA

• Recent study (Frat et al. NEJM 2015)
  • 310 ARF patients compared HFNC, oxygen support, NIV
  • No significant difference obtained in terms of intubation rates
  • Treatment with HFNC was associated with higher number ventilator free days at day 28 and a better 90 day mortality rate

• Another study (Kang et al. Intensive Care Med 2015)
  • Delayed intubation after HFNC trial is associated with adverse outcomes: poor weaning, fewer ventilator free days, and increased mortality

• Strong data are still lacking before suggesting HFNC instead of NIV/PAP as first line treatment in critically ill patients
HOW DO WE SUPPLY NIPPV TO THE PATIENT? ADAPTIVE SERVO-VENTILATION

• Specifically used to treat central sleep apnea
• Designed to vary support according to a patient’s individual breathing rate
• Automatically calculates a target ventilation
• Automatically adjusts pressure support to achieve target ventilation
• Not recommended for patients with systolic CHF
• Not used in acute setting
CASE PRESENTATION

- HPI: 75 yo WM with a hx of severe COPD and OSA, noncompliant with PAP therapy but wears oxygen 2 lpm hs, presents to the hospital with AECOPD. After several bronchodilator treatments he remains dyspneic, wheezing, and using accessory muscles to breathe.

- VS: T 37.2C, BP 160/95 mmHg, HR 100 bpm, RR 32 bpm, 98kg, 65 in height

- Exam AAOx3, mild respiratory distress, RRR no m/r/g, Decreased BS with expiratory wheeze bilaterally, Abdomen benign, Extremities without c/c/e

- Labs: ABG 7.25/60/65/ on 3 lpm oxygen

- CXR: hyperinflation, no infiltrates, effusion, edema
CLINICAL MONITORING

- Subjective response
  - Bedside observation
- Physiologic response
  - Improved hemodynamics (RR HR BP)
  - Patient in synchrony with NIV device
  - Decreased WOB
  - Improved TV
- Objective response
  - Improved gas exchange (ABG)
    - Check ABG 1 h after initiation and 1 h after every change in settings
    - Clinical judgement
  - Continuous EKG and pulse oximetry monitoring
PREDICTORS OF NIV FAILURE

• Unable to reverse underlying cause/disease process
• Unable to correct acid/base derangement (within first two hours)
• Persistent hypoxemia
• Hemodynamic instability
• Altered mental status
• Edentulous
• Excessive secretions
• Inability to tolerate interface
• Older age
CAUSES OF FAILURE OF NONINVASIVE MECHANICAL VENTILATION

The reported NPPV failure rate is 5–40%.

With patients suffering hypercapnic respiratory failure the best NPPV success/failure predictor is the degree of acidosis/acidemia (pH and PaCO2 at admission and after 1 hour on NPPV).

Whereas mental status and severity of illness are less reliable predictors.

With patients suffering hypoxic respiratory failure the likelihood of NPPV success seems to be related to the underlying disease rather than to the degree of hypoxia.

For example, the presence of acute respiratory distress syndrome or community-acquired pneumonia portends NPPV failure, as does lack of oxygenation improvement after an hour on NPPV.

Stefano Nava MD and Piero Ceriana MD
Respir Care 2004;49(3):295–303. © 2004
<table>
<thead>
<tr>
<th>Complication</th>
<th>Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>Air leak</td>
<td>Ensure that the mask is the correct size and has been fitted correctly.</td>
</tr>
<tr>
<td></td>
<td>Use a mask of a different size or type.</td>
</tr>
<tr>
<td></td>
<td>Tighten the straps.</td>
</tr>
<tr>
<td></td>
<td>Reduce airway pressures, if possible.</td>
</tr>
<tr>
<td>Skin irritation or abrasion</td>
<td>Loosen the straps.</td>
</tr>
<tr>
<td></td>
<td>Use a mask of a different size or type.</td>
</tr>
<tr>
<td></td>
<td>Apply artificial skin or a dressing over the affected area.</td>
</tr>
<tr>
<td>Claustrophobia</td>
<td>Redirect the patient by having the patient watch television, talking to</td>
</tr>
<tr>
<td></td>
<td>the patient, or having a family member talk to the patient.</td>
</tr>
<tr>
<td></td>
<td>Use a less obtrusive mask (e.g., nasal pillows).</td>
</tr>
<tr>
<td></td>
<td>Consider inducing light sedation in the patient.</td>
</tr>
<tr>
<td>Nasal congestion, sinus pain, or ear pain</td>
<td>Provide topical decongestants or antihistamines if there are no contra-</td>
</tr>
<tr>
<td></td>
<td>indications.</td>
</tr>
<tr>
<td></td>
<td>Humidify the inspired air.</td>
</tr>
<tr>
<td></td>
<td>Reduce airway pressures, if possible.</td>
</tr>
<tr>
<td>Mucosal dryness</td>
<td>Humidify the inspired air.</td>
</tr>
<tr>
<td></td>
<td>If a nasal mask is being used, apply a chin strap to reduce air flow</td>
</tr>
<tr>
<td></td>
<td>through the mouth.</td>
</tr>
<tr>
<td>Mucus plugging</td>
<td>Humidify the inspired air.</td>
</tr>
<tr>
<td></td>
<td>Give the patient brief breaks from ventilation, if possible, and perform</td>
</tr>
<tr>
<td></td>
<td>maneuvers that will help to clear the airway, such as chest percussion.</td>
</tr>
<tr>
<td></td>
<td>Reduce airway pressures, if possible.</td>
</tr>
<tr>
<td>Pulmonary barotrauma or pneumothorax</td>
<td>Stop ventilation or, at minimum, reduce airway pressures. Insert</td>
</tr>
<tr>
<td></td>
<td>chest tube, if appropriate.</td>
</tr>
</tbody>
</table>
ASSOCIATION OF NIV WITH NOSOCOMIAL INFECTIONS AND SURVIVAL IN CRITICALLY ILL PATIENTS

• Retrospective, observational cohort study
• 948 patients (COPD or severe CPE)
• 1994-2001
• 521 required ventilation
• 42 excluded
• 479 included in study cohort
• 313 (65%) received NIV
• 166 (35%) received ETI

Girou et al. JAMA. 2003;290:2985
ASSOCIATION OF NIV WITH NOSOCOMIAL INFECTIONS AND SURVIVAL IN CRITICALLY ILL PATIENTS

Girou et al. JAMA. 2003;290:2985
CONCLUSION

• In 1977, a former editor in chief of Respiratory Care, wrote:

  • “CPAP is no longer a new therapy, nor, alas, is the strapped positive-pressure breathing mask a new device. It is, rather, as antiquated as it is inhumane and unsafe...A patient who is sick enough to need CPAP is sick enough to need an endotracheal tube.”

Hess D. Noninvasive Ventilation For Acute Respiratory Failure Respiratory Care 2013; 58(6): 950-69
CONCLUSION

• NIPPV has radically changed the management of ARF.
• Possible applications of NIV have increased.
• NIPPIV is no longer confined to the ICU, but has regular ward, ED and ‘out-of-hospital’, pre-hospital environment.
• Current research is focusing on improving the quality and safety of the devices and establishing new ventilatory modes in order to extend even further the indications to NIV as well as its rate of success.
Just Keep Breathing